Abstract
Mycophenolate mofetil (MMF) is licensed as a prophylaxis in combination therapy to prevent renal transplant rejection. Gastrointestinal side effects are fairly common and include diarrhoea, abdominal discomfort, nausea, vomiting, gastritis and constipation. This drug has recently been described as causing villous atrophy, nutrient malabsorption and colonic mucosal changes. We present a case of reversible steatorrhoea occurring in a patient treated with MMF following an episode of infections diarrhoea.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Davies NM, Grinyo J, Heading R, Maes B, Meier-Kriesche H, Oellerich M. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Neph Dial Transplant. 2007;22:2440–8.
Bunnapradist S, Neri L, Wong W, Lentine KL, Burroughs TE, Pinsky BW, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis. 2008;51:478–86.
Kamar N, Faure P, Dupuis E, Coinault O, Joseph-Hein K, Durand D, et al. Villous atrophy induced by mycophenolate mofetil in renal transplant patients. Transplant Int. 2004;17:463–7.
Ducloux D, Ottigon Y, Semhoun-Doucloux S, Labbe S, Saint-Hillier Y, Miguet JP, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation. 1998;66:1115–6.
Pally C, Tanner M, Rizvi H, Papageorgiou C, Schuurman HJ. Tolerability profile of sodium mycophenolate (ERL0800 and mycophenolate mofetil with and without cyclosporine (neoral) in the rat. Toxicology. 2001;157:207–15.
Maes BD, Dalle I, Geboes K, Oellerich M, Armstrong VW, Evenepoel P, Geypens B, Kuypers D, Shipkova M, Geboes K, Vanrenterghem YF. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation. 2003;75(5):665–72.
Dalle IJ, Maes BD, Geboes KP, Lemahieu W, Geboes K. Crohn’s-like changes in the colon due to mycophenolate? Colorectal Dis. 2005;7(1):27–34.
Moelle DD. Steatorrhoea associated with meclofenamate sodium therapy. Am J Gastroenterol. 1987;82:1320–1.
Rahman F, Cain GD. Drug-induced malabsorption: a review. South Med J. 1973;66:724–5.
Wilson DW, Wilson HC. Studies in vitro of the digestion and absorption of purine nucleotides by the intestine. J Biol Chem. 1962;237:1643–7.
Shipkova M, Spielbauer B, Voland A, Gröne HJ, Armstrong VW, Oellerich M, et al. cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. Transplantation. 2004;78:1145–52.
Fine KD, Fordtan JS. The effect of diarrhoea on fecal fat excretion. Gastroenterology. 1992;102:1936–9.
Laskin B, Goebel J. Clinically “silent” weight loss associated with mycophenolate mofetil in pediatric renal transplant recipients. Pediatr Transplantation. 2008;12:113–6.
Walters JRF. Investigation of gastrointestinal function. In: Warrel DA, Cox TM, Firth JD, Denz EJ, editors. Oxford textbook of medicine. Oxford, UK:Oxford University Press: 2003. p. 504.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tagboto, S., Akhtar, F. Steatorrhoea complicating post-infectious diarrhoea in a renal transplant patient on mycophenolate mofetil therapy. Clin Exp Nephrol 13, 182–184 (2009). https://doi.org/10.1007/s10157-008-0109-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-008-0109-7